Savient meets filing deadline for required Nasdaq reports

By Lisa Kerner

Erie, Pa., Jan. 26 - Savient Pharmaceuticals, Inc. said it believes the company is in compliance with all listing requirements of The Nasdaq National Market with the filing of its form 10-Q for the third quarter of 2005. The form was filed with the Securities and Exchange Commission on Thursday, according to a company news release.

The company said it will continue to work with its financial consultants to modify as necessary its financial processes and procedures.

The form 10-Q filing, as well as Savient's 2005 form 10-K amendment and its forms 10-Q for the quarters ended March 31 and June 30, 2005, remain subject to review by the Nasdaq staff to determine completion.

Savient said it anticipates that Nasdaq will acknowledge the company's compliance with the terms of the panel's decision and Nasdaq filing requirements.

Once compliance is met, the fifth character "E" would be removed from Savient's trading symbol. The company said it could then resume trading under its original trading symbol "SVNT."

Savient Pharmaceuticals is an emerging specialty pharmaceuticals company based in East Brunswick, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.